Format

Send to

Choose Destination
Clin Sci (Lond). 2016 Nov 1;130(21):1929-37. doi: 10.1042/CS20160268. Epub 2016 Aug 19.

Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes.

Author information

1
National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, via Ugo La Malfa 153, 90146 Palermo, Italy fabio.cibella@ibim.cnr.it.
2
Centro per la Prevenzione e Cura del Tabagismo, Azienda Ospedaliero-Universitaria "Policlinico-V. Emanuele", University of Catania, Via S. Sofia 78, 95123 Catania, Italy Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria "Policlinico-V. Emanuele", University of Catania, Via S. Sofia 78, 95123 Catania, Italy.
3
Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria "Policlinico-V. Emanuele", University of Catania, Via S. Sofia 78, 95123 Catania, Italy.
4
Division of Respirology, Critical Care and Sleep Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK, Canada S7N0W8.

Abstract

Quitting smoking is the most important step smokers can take to improve their health. Nonetheless, there is little information on long-term improvements in lung function and/or respiratory symptoms after smoking cessation. Here we illustrate long-term changes in spirometric indices as well as in respiratory symptoms in smokers invited to quit or reduce their cigarette consumption by switching to electronic cigarettes (ECs). Prospective evaluation of cigarette consumption, spirometry and symptoms was performed in a 1-year randomized controlled trial of smokers receiving EC containing 2.4%, 1.8% or 0% nicotine. Spirometric data are presented on the basis of participants' pooled continuous smoking phenotype classification (Quitters, Reducers, Failures), whereas respiratory symptoms on the basis of their point prevalence-smoking phenotype. Smoking phenotype classification (Quitters, Reducers, Failures) had no significant effect on spirometric indices (FEV1, FVC and FEV1/FVC) with the exception of FEF25-75%, which significantly (P  =0.034) increased over the time among Quitters; their FEF25-75% (% predicted) improving from (means±S.D.) 85.7±15.6% at baseline (BL) to 100.8±14.6%. High prevalence of cough/phlegm (43.1%) and shortness of breath (SoB; 34.8%) was reported at BL with substantial reduction in their frequency at subsequent follow-up visits. These symptoms virtually disappeared very quickly in both quitters and reducers. Smokers invited to switch to ECs who completely abstained from smoking showed steady progressive improvements in their FEF25-75% Normalization of peripheral airways function was associated with improvement in respiratory symptoms, adding to the notion that abstaining from smoking can reverse tobacco harm in the lung.

KEYWORDS:

electronic cigarettes; respiratory function tests; respiratory symptoms; smoking cessation; tobacco harm reduction

PMID:
27543458
DOI:
10.1042/CS20160268
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center